Sign in Subscribe

Caribou Biosciences Jumps as FDA Grants RMAT Designation to Off-the-Shelf CAR-T Therapy CB-011 for Multiple Myeloma

Caribou Biosciences stock surges after FDA grants RMAT designation to CB-011, its off-the-shelf allogeneic CAR-T for multiple myeloma. Phase 1 data: 92% ORR, 75% complete response in BCMA-naïve patients. More data expected 2026.

Caribou Biosciences Jumps as FDA Grants RMAT Designation to Off-the-Shelf CAR-T Therapy CB-011 for Multiple Myeloma
Credit: Caribou Biosciences
Already have an account? Sign in.